SCHEMBL7572703

SCHEMBL7572703

CCOP(N(C(C)C)C(C)C)N(C(C)C)C(C)C

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14064163 0.80
SCHEMBL19890099 0.79 HSD17B10 (0.31)
SCHEMBL386368 0.78 LMNA (0.30) LMNA
SCHEMBL4342842 0.75 ADRB2 (0.33)
SCHEMBL1391357 0.74
SCHEMBL3624139 0.74
SCHEMBL15314806 0.74
SCHEMBL21178189 0.74 CA1 (0.34)
SCHEMBL21178019 0.72 SPHK1 (0.37)
SCHEMBL21178108 0.72 SPHK1 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025047679-A1 STABLE TARGET EDITING GUIDE RNA HAVING PHOSPHATE MOIETY MODIFICATION INTRODUCED THEREINTO 学校法人福岡大学 2025-03-06 WO disclosed
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators ALIGOS THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
US-20230303614-A1 CAPPING COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF SEATTLE PROJECT CORP. 2023-09-28 US disclosed
US-20230119227-A1 OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT INTEGRATED DNA TECHNOLOGIES, INC. 2023-04-20 US disclosed
EP-4110789-A1 OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT Integrated Dna Technologies, Inc. (US) 2023-01-04 EP disclosed
US-20200369711-A1 MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS ALIGOS THERAPEUTICS, INC. 2020-11-26 US disclosed
US-20200369703-A1 Modified oligonucleotides and compound that can be used for synthesizing same GUANGZHOU RIBOBIO CO LTD (CN) 2020-11-26 US disclosed
US-20190112328-A1 DIARYLSULFIDE BACKBONE CONTAINING PHOTOLABILE PROTECTING GROUPS NIMBLEGEN SYSTEMS GMBH (DE) 2019-04-18 US disclosed
EP-2696679-B1 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME (US) 2017-08-02 EP disclosed
WO-2012142093-A2 2'-CYANO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2012-10-18 WO disclosed
EP-0751948-B1 NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS INC (US) 2002-09-25 EP disclosed
US-5717083-A COMPLEXING WITH PROTEINS, NUCLEIC ACIDS, LIPIDS ISIS PHARMACEUTICALS, INC. (US) 1998-02-10 US disclosed
US-5637684-A BINDING PROTEINS, NUCLEIC ACIDS, LIPIDS; PHOSPHOLIPASE INHIBITOR ISIS PHARMACEUTICALS, INC. (US) 1997-06-10 US disclosed
EP-0751948-A4 NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS INC (US) 1997-03-19 EP disclosed
EP-0751948-A1 NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1997-01-08 EP disclosed
WO-1996029337-A1 THIONO TRIESTER MODIFIED ANTISENSE OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATES HYBRIDON, INC. (US) 1996-09-26 WO disclosed
WO-1995023160-A1 NOVEL PHOSPHORAMIDATE AND PHOPHOROTHIOAMIDATE OLIGOMERIC COMPOUNDS ISIS PHARMACEUTICALS, INC. (US) 1995-08-31 WO disclosed
EP-0229053-A1 METHOD FOR SYNTHESIZING DEOXYOLIGONUCLEOTIDES UNIVERSITY PATENTS, INC. (US) 1987-07-22 EP disclosed
WO-1986007362-A1 METHOD FOR SYNTHESIZING DEOXYOLIGONUCLEOTIDES UNIVERSITY PATENTS, INC. (US) 1986-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303614-A1 CAPPING COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF RNGTT, RNMT, NSUN2 LMNA 1820/4885
US-20200369703-A1 Modified oligonucleotides and compound that can be used for synthesizing same POLRMT, RNASE1, ADAR LMNA 1108/4885
US-20200369711-A1 MODIFIED CYCLIC DINUCLEOSIDE COMPOUNDS AS STING MODULATORS STING1, CGAS, IRF3 LMNA 825/4885
US-20190112328-A1 DIARYLSULFIDE BACKBONE CONTAINING PHOTOLABILE PROTECTING GROUPS CRY2, PRXL2A, MGMT LMNA 2105/4885
US-11787833-B2 Modified cyclic dinucleoside compounds as sting modulators STING1, CGAS, IRF3 LMNA 825/4885
US-20230119227-A1 OLIGONUCLEOTIDE SYNTHESIS ON SOLID SUPPORT RNGTT, SSU72, NSUN2 LMNA 1861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.